Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 4, 2007, Pages 1296-1304

  Delmas, Pierre D ^a   Vrijens, Bernard ^b   Eastell, Richard ^c   Roux, Christian ^d   Pols, Huibert A P ^e   Ringe, Johann D ^f   Grauer, Andreas ^g   Cahall, David ^h   Watts, Nelson B ⁱ  

^a UNIVERSITÉ LYON 1   (France)

^b AARDEX Group   (Switzerland)

^c Northern General Hospital   (United Kingdom)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f KLINIKUM LEVERKUSEN   (Germany)

^g PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^h SANOFI   (France)

ⁱ UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CALCIUM; COLLAGEN TYPE 1; RISEDRONIC ACID; VITAMIN D;

AGED; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REINFORCEMENT; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

EID: 34147128320     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1526     Document Type: Article

References (35)

1. Cooper C, Atkinson EJ, O'Fallon WM, Melton 3rd LJ 1992 Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 7:221-227
2. Iqbal MM 2000 Osteoporosis: epidemiology, diagnosis, and treatment. South Med J 93:2-18
3. NIH Consensus Development Panel on Osteoporosis Prevention D, and Therapy 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
4. Miller NH 1997 Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43-49
5. Zyczynski TM, Coyne KS 2000 Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep 2:510-514
6. Schroeder K, Fahey T, Ebrahim S 2004 How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 164:722-732
7. Conlin PR, Gerth WC, Fox J, Roehm JB, Boccuzzi SJ 2001 Four-year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes. Clin Ther 23:1999-2010
8. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J 2002 Long-term persistence in use of statin therapy in elderly patients. JAMA 288:455-461
9. Jackevicius CA, Mamdani M, Tu JV 2002 Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 288:462-467
10. Clowes JA, Peel NF, Eastell R 2004 The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117-1123
11. Papaioannou A, Ioannidis G, Adachi JD, Sebaldt RJ, Ferko N, Puglia M, Brown J, Tenenhouse A, Olszynski WP, Boulos P, Hanley DA, Josse R, Murray TM, Petrie A, Goldsmith CH 2003 Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database. Osteoporos Int 14:808-813
12. Turbi C, Herrero-Beaumont G, Acebes JC, Torrijos A, Grana J, Miguelez R, Sacristan J, Marin F 2004 Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26:245-256
13. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J 2004 Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271-287
14. Watts NB, Worley K, Solis A, Doyle J, Sheer R 2004 Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 10:142-151
15. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C 2004 The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008
16. Cleemput I, Kesteloot K, DeGeest S 2002 A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 59:65-94
17. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J 2000 The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(Suppl 6):S2-S17
18. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056
19. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD 2004 Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394-401
20. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922-930
21. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD, for the Fracture Intervention Trial Study Group 2004 Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 19:1250-1258
22. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148
23. Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A, Cahall DL, for the IMPACT Study Group 2005 Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 20:557-563
24. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R 2000 Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
25. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, for the Hip Intervention Program Study Group 2001 Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340
26. Donner A, Klar N 2000 Design and analysis of cluster randomization trials in health design. London: Arnold, a member of the Hodder Headline Group; 128-138
27. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut 3rd CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD 1999 Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344-1352
28. Levine RJ 1994 Monitoring for adherence: ethical considerations. Am J Respir Crit Care Med 149(2 Pt 1):287-288
29. Rand CS, Sevick MA 2000 Ethics in adherence promotion and monitoring. Control Clin Trials 21(5 Suppl):241S-247S
30. Simmons MS, Nides MA, Rand CS, Wise RA, Tashkin DP 2000 Unpredictability of deception in compliance with physician-prescribed bronchodilator inhaler use in a clinical trial. Chest 118:290-295
31. Rosen MI, Rigsby MO, Salahi JT, Ryan CE, Cramer JA 2004 Electronic monitoring and counseling to improve medication adherence. Behav Res Ther 42:409-422
32. Buelow JM, Smith MC 2004 Medication management by the person with epilepsy: perception versus reality. Epilepsy Behav 5:401-406
33. Haynes RB, McDonald HP, Garg AX 2002 Helping patients follow prescribed treatment: clinical applications. JAMA 288:2880-2883
34. McDonald HP, Garg AX, Haynes RB 2002 Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 288:2868-2879
35. Deal CL 2001 Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons. Curr Rheumatol Rep 3:233-239